Study ID	Methods	Participants	Intervention	Outcomes	Notes
Bratusch‐Marrain 1979Multiple pub: No	Study design: RCTRandomization procedure: Random number tablesAllocation concealment: AdequateFollow‐up: 8w	Country: AustriaSetting: UnclearNumber: 40Age: 50Sex: 66%FMedications: NRBL wt: I 80.3, C 93.9BL BMI: I 30.8, C 41.7BL GHb: NR	Drug: DiethylpropionDosage: 75mg qdDuration: 8wDiet: NRComparison: Placebo	Weight: YesBMI:>5% loss (%):FBS:GHb:Cholesterol:LDL:HDL:TG:SBP:DBP:Side effects:	Funding: NRAbstract/full text: FTLOCF: NR ITT: Yes, with attritionAttrition: 20%Blinding: Double‐blindBlinding assessor: YesBL comparable: YesJadad score: 1,1,1,BRisk of bias: B
Hendon 1962Multiple pub:No	Study design: Pre‐versus‐postRandomization procedure: NAAllocation concealment: NAFollow‐up: 2 to 19m	Country: USASetting: academic endocrine clinicNumber: 40Age: 51ySex: NRMedications: NoneBL wt: 85BL BMI: NRBL GHb: NR	Drug: DiethylpropionDosage: 25‐75mg tidDuration: 40wDiet: noneComparison: NA	Weight: YesBMI:>5% loss (%):FBS:GHb:Cholesterol:LDL:HDL:TG:SBP:DBP:Side effects: YesHeadache, lightheaded, nausea; no incidence given	Funding: NRAbstract/full text: FTLOCF: NRITT: Yes, with attritionAttrition: 25%Blinding assessor: NoBL comparable: NAJadad score: NARisk of bias: NA
Montenero 1964ItalianMultiple pub: No	Study design: Two study groups; pre‐versus‐postRandomization procedure: NAAllocation concealment: NAFollow‐up: 20‐240d	Country: ItalySetting: NRNumber: 50Age: 54Sex: 65%FMedications: 17% insulin; 67% oral agentsBL wt: I 97 , C 92 BL BMI: NRBL GHb: NR	Drug: DiethylpropionDosage: 2‐3qd (dosage not specified)Duration: 20‐240dDiet: 1000‐1800kcal/dComparison: Both groups got same diet and dosage diethylpropion; group A was on hypoglycemic agents, group B was diet controlled	Weight: YesBMI:>5% loss (%):FBS: YesGHb:Cholesterol:LDL:HDL:TG:SBP:DBP:Side effects: Yes; per Pina: 4/50 quit for SE, including general malaise, epigastric disturbance, and dermatitis. No untoward effects in person with HT and CVD; normal LFT and renal function	Funding: NRAbstract/full text: FTLOCF: NRITT: Yes, with attritionAttrition: 8%Blinding assessor: NRBL comparable: NRJadad score: NARisk of bias: NA
Silverstone 1966Multiple pub: No	Study design: RCTRandomization procedure: NRAllocation concealment: UnclearFollow‐up: 26w	Country: EnglandNumber: 50Age: 56Sex: 80%FMedications: 56% diet only; no insulinBL wt: I 84.4, C 89.4BL BMI: NRBL GHb: NR	Drug: DiethylpropionDosage: 75mg qd; 40% 3w on, 3w off; 60% 5w on, 5w off Duration: 26wDiet: 1000kcal/dComparison: Placebo + diet	Weight: YesBMI:>5% loss (%):FBS:GHb:Cholesterol:LDL:HDL:TG:SBP:DBP:Side effects: Yes; dry mouth in 2/15 pts	Funding: Merrell‐National Laboratories, Ltd. supplied drugAbstract/full text: FTLOCF: NRITT: Yes, with attritionAttrition: 20%Blinding: Double‐blindBlinding assessor: YesBL comparable: NRJadad score: 1,1,1,BRisk of bias: B
Williams 1968Multiple pub: No	Study design: RCTRandomization procedure: random number tableAllocation concealment: adequateFollow‐up: 8w	Country: EnglandSetting: UnclearNumber: 63Age: 58Sex: 89%FMedications: NoneBL wt: NRBL BMI: NRBL GHb: NR	Drug: DiethylpropionDosage: 75mg qdDuration: 8wDiet: Low fatComparison: Placebo + diet	Weight: YesBMI:>5% loss (%):FBS:GHb:Cholesterol:LDL:HDL:TG:SBP:DBP:Side effects: Yes; no SE on drug; one with placebo	Funding: John Wyeth and BrotherAbstract/full text: FTLOCF: NoITT: Yes, with attritionAttrition: 22%Blinding: Double‐blindBlinding assessor: NRBL comparable: NRJadad score: 2,1,1,ARisk of bias: B